Rezultati

eNauka >  Results >  A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study
Title: A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study
Authors: Unseld M.; Belic J.  ; Pierer K.; Zhou Q.; Moser T.; Bauer R.; Piringer G.; Gerger A.; Siebenhüner A.; Speicher M.;
Heitzer E.;
Issue Date: 2021
Publication: International Journal of Cancer
ISSN: 0020-7136 International Journal of Cancer Search Idenfier
Type: Article
Collation: vol. 148 br. 6 str. 1452-1461
DOI : 10.1002/ijc.33303.
URI: https://www.cris.uns.ac.rs/record.jsf?recordId=131586&source=eNauka&language=en
https://enauka.gov.rs/handle/123456789/790539
M-category: 
21aM21a

Alt metrika
Dimensions
Unpaywall

Rezultati na eNauka su zaštićeni autorskim pravima i sva prava su zadržana, osim ako nije drugačije naznačeno.